Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PKA Iα reg CRISPR/Cas9 KO Plasmid (m): sc-422400
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PKA Iα reg CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PKA Iα reg genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PKA Iα reg Antibody (20): sc-136231
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PKA Iα reg CRISPR/Cas9 KO Plasmid (m) | sc-422400 | 20 µg | $397.00 |
Overview
Prkar1a encodes the type I regulatory subunit alpha of cAMP-dependent protein kinase A (PKA), a key negative regulator that binds catalytic subunits and restrains kinase activity until cAMP induces holoenzyme dissociation. Through control of PKA signaling, PRKAR1A influences phosphorylation programs governing metabolism, cell-cycle progression, differentiation, and transcriptional responses downstream of GPCR–adenylyl cyclase–cAMP pathways. In mouse systems, perturbation of Prkar1a alters cAMP/PKA pathway dynamics with downstream effects on CREB-regulated gene expression and broader signaling crosstalk, including MAPK-associated processes. Dysregulation of PRKAR1A and cAMP/PKA signaling has been linked to endocrine and growth-control phenotypes, making it a relevant target for studying signaling-dependent disease mechanisms in vivo and in cultured cells.
PKA Iα reg CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Prkar1a gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Prkar1a together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Prkar1a open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PKA Iα reg protein expression.
This CRISPR knockout system enables efficient generation of Prkar1a-deficient cell models for investigation of PKA Iα reg signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Prkar1a exon(s) critical for PKA Iα reg function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Prkar1a genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PKA Iα reg CRISPR/Cas9 KO Plasmid (m) and PKA Iα reg CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Prkar1a locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PKA Iα reg HDR Plasmid (m) and PKA Iα reg HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Prkar1a homology arms to support homology-directed repair at defined Prkar1a target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.